BPC-157 / TB-500
Co-Formulated Research Blend - Co-formulated repair-research blend in a single vial.
A co-formulated blend pairing BPC-157 and TB-500 at a 1:1 ratio, prepared for researchers studying the two compounds in combination within tissue-repair protocols.
Combination work exists because the two peptides are reported to act through non-overlapping mechanisms - one weighted toward angiogenic and cytoprotective signaling, the other toward actin regulation and cell migration. Co-formulating them at a fixed ratio removes a source of preparation variability when both are studied together.
BPC-157 / TB-500 specifications
- Molecular formula
- Co-formulated blend
- Sequence
- 10mg BPC-157 + 10mg TB-500
- Residues
- BPC-157 (15) + TB-500 (43)
- Presentation
- Lyophilized powder
- Documented purity
- 99.90% by HPLC
- Available sizes
- 20mg ($75)
- Archived COA lots
- 10
- Intended use
- Laboratory research use only. Not for human or veterinary use.
Studied pathways
- Combined repair signaling - Investigated for overlapping angiogenic and actin-regulating activity when the two peptides are studied together.
Reported mechanisms in the literature
- Overlapping repair signaling - Studied for the overlap between BPC-157's angiogenic/cytoprotective activity and TB-500's actin-regulating, migration-promoting activity when the two are researched together. (Combination research)
- Vessel formation & cell movement - Investigated as a paired system in tissue-repair protocols - one component associated with new-vessel signaling, the other with reparative cell migration. (Preclinical literature)
What BPC-157 / TB-500 is researched for
- Combined recovery - Studied as a paired preparation for tendon, muscle and connective-tissue repair endpoints. (Combination research)
- Angiogenic repair - Investigated for combined angiogenic and cell-migration activity in wound models. (Preclinical literature)
BPC-157 / TB-500 certificates of analysis on file
Every lot below was tested by an independent laboratory and the full report is published as a PDF. Purity is shown exactly as the report states it. The same records are searchable in the COA library and can be checked on the lot verification page.
| Lot | Tested | Size | Laboratory | HPLC purity | Identity | Certificate |
|---|---|---|---|---|---|---|
| BPC-TB-101926-20 | 22 Oct 2026 | 20mg | ILS Laboratories | 99.76% | Confirmed (HPLC retention time) | COA PDF |
| 6UC3KJ | 3 Oct 2026 | 20mg | Freedom Diagnostics | 99.88% | Confirmed (LC-MS/MS) | COA PDF |
| Auth2605270304 | 30 May 2026 | 20mg | Freedom Diagnostics | 99.67% | Confirmed (LC-MS/MS) | COA PDF |
| Auth2605270309 | 30 May 2026 | 20mg | Freedom Diagnostics | 99.80% | Confirmed (LC-MS/MS) | COA PDF |
| FD-2605270304 | 27 May 2026 | 10mg | Freedom Diagnostics | 99.67% | Confirmed (LC-MS/MS) | COA PDF |
| FD-2605210573 | 23 May 2026 | 10mg | Freedom Diagnostics | 99.30% | Confirmed (LC-MS/MS) | COA PDF |
| Whol2605210573 | 23 May 2026 | 20mg | Freedom Diagnostics | 99.30% | Confirmed (LC-MS/MS) | COA PDF |
| BPTB20-032026-1 | 21 Mar 2026 | 20mg | Freedom Diagnostics | 99.39% | Confirmed (LC-MS/MS) | COA PDF |
| 1000001 | 20 Feb 2026 | 20mg | Freedom Diagnostics | 99.90% | Confirmed (LC-MS/MS) | COA PDF |
| FD-2602180085 | 18 Feb 2026 | 10mg | Freedom Diagnostics | 99.90% | Confirmed (LC-MS/MS) | COA PDF |
Published literature on BPC-157 / TB-500
The mechanisms above trace to peer-reviewed studies indexed on PubMed. These are independent third-party publications, not Aspect Peptides claims. Browse indexed research on PubMed.
BPC-157 / TB-500 frequently asked questions
Why combine BPC-157 and TB-500?
Researchers study the two together because their reported repair mechanisms are complementary - angiogenic/cytoprotective versus actin-regulating/migratory. This blend co-formulates both at a 1:1 ratio for combination studies.
Is this blend approved for human use?
No. Neither component is approved for human use, and the blend is a research material only. All data is preclinical.
How is the blend documented?
The vial ships with a Certificate of Analysis covering the combined lot. Each component's identity and purity are established before release.
Documented to 99.90% purity by HPLC · third-party COA every lot · from $75 · For laboratory research use only.
Related Regenerative & Repair compounds
- BPC-157 - Synthetic pentadecapeptide studied for VEGF and growth-factor receptor signaling.
- TB-500 - Thymosin β-4 fragment studied for actin regulation and tissue repair.
- BPC-157 / TB-500 / KPV - BPC-157, TB-500 and KPV co-formulated in a single vial.
- GHK-Cu - Copper tripeptide studied in skin-remodeling research.
- KPV - α-MSH C-terminal fragment studied for inflammatory signaling.
- ARA-290 - Erythropoietin-derived peptide studied for neural repair.